Article info

PDF

Original article
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Authors

  1. Correspondence to PD Dr Tania M Welzel M.H.Sc., Department of Medicine 1, Johann Wolfgang Goethe-University Hospital, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main Germany; tania.welzel{at}kgu.de
View Full Text

Citation

Welzel TM, Petersen J, Herzer K, et al
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Publication history

  • Received June 14, 2016
  • Revised July 21, 2016
  • Accepted August 9, 2016
  • First published September 7, 2016.
Online issue publication 
October 07, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.